Last updated on May 2018

TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)


Brief description of study

This multiple-center, 3-Cohort, single-blind dose escalation (Cohort 1), randomized, double-blind (Cohort 2), and open-label multiple dose extension (Cohort 3C) study will be conducted in male and female subjects with neurogenic orthostatic hypotension to evaluate the effect of TD-9855 in improving symptoms of orthostatic intolerance.

Clinical Study Identifier: NCT02705755

Contact Investigators or Research Sites near you

Start Over

Omid Omidvar, MD

Collaborative Neuroscience Network, LLC.
Long Beach, CA United States

Aaron Ellenbogen, D.O.

Quest Research Institute
Farmington Hills, MI United States

Michael Hassman, M.D.

Hassman Research Institute
Berlin, NJ United States

Horacio Kaufmann, MD

NYU Langone Medical Center
New York, NY United States

Italo Biaggioni, MD

Vanderbilt University Medical Center
Nashville, TN United States

Meredith Bryarly, MD

University of Texas Southwestern Medical Center
Dallas, TX United States